



Review

K_{Ca}2 and K_{Ca}3.1 Channels in the Airways: A New Therapeutic Target

Razan Orfali ^{1,2}, Ali AlFaiz ², Mohammad Asikur Rahman ¹, Liz Lau ¹, Young-Woo Nam ^{1,*} and Miao Zhang ^{1,*}

¹ Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA; rorfali@kfmc.med.sa (R.O.)

² Biomedical Research Administration, Research Centre, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 12231, Saudi Arabia

* Correspondence: ywnam@chapman.edu (Y.-W.N.); zhang@chapman.edu (M.Z.)

Abstract: K⁺ channels are involved in many critical functions in lung physiology. Recently, the family of Ca²⁺-activated K⁺ channels (K_{Ca}) has received more attention, and a massive amount of effort has been devoted to developing selective medications targeting these channels. Within the family of K_{Ca} channels, three small-conductance Ca²⁺-activated K⁺ (K_{Ca}2) channel subtypes, together with the intermediate-conductance K_{Ca}3.1 channel, are voltage-independent K⁺ channels, and they mediate Ca²⁺-induced membrane hyperpolarization. Many K_{Ca}2 channel members are involved in crucial roles in physiological and pathological systems throughout the body. In this article, different subtypes of K_{Ca}2 and K_{Ca}3.1 channels and their functions in respiratory diseases are discussed. Additionally, the pharmacology of the K_{Ca}2 and K_{Ca}3.1 channels and the link between these channels and respiratory ciliary regulations will be explained in more detail. In the future, specific modulators for small or intermediate Ca²⁺-activated K⁺ channels may offer a unique therapeutic opportunity to treat muco-obstructive lung diseases.

Keywords: K_{Ca}2 channels; lungs; motile cilia; cystic fibrosis; anosmia; chronic obstructive pulmonary diseases



Citation: Orfali, R.; AlFaiz, A.; Rahman, M.A.; Lau, L.; Nam, Y.-W.; Zhang, M. K_{Ca}2 and K_{Ca}3.1 Channels in the Airways: A New Therapeutic Target. *Biomedicines* **2023**, *11*, 1780. <https://doi.org/10.3390/biomedicines11071780>

Academic Editor: Te-Chun Shen

Received: 22 May 2023

Revised: 8 June 2023

Accepted: 13 June 2023

Published: 21 June 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The epithelial surface of the respiratory tract between the nose and the alveoli is constantly exposed to potentially harmful pathogens, particulates, and gaseous materials [1–3]. In response to these challenges, the human body utilizes a series of defense mechanisms to protect the airways, and the primary defense mechanism in the lung is mucociliary clearance (MCC) [1,4]. MCC is a process of specialized organelles called cilia that beat in metachronal waves to impel pathogens and particles trapped by the mucous layer out of the airways. Cilia within the mucociliary system present critical functions in human health; abnormalities in each compartment of the mucociliary system could compromise the mucus clearance process and lead to chronic lung disease [2,3]. Mucociliary dysfunction is commonly associated with chronic airway diseases, and it is one of the pathological observations in patients with cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, and asthma [5,6]. Airway diseases with associated mucociliary dysfunction remain largely unaddressed, despite the therapeutic progress in treating inflammatory lung diseases [5].

The lung's lining is covered by a thin layer of fluid called airway surface liquid (ASL); it separates the airway epithelium's luminal surface from the external environment. ASL is mainly composed of water, electrolytes, and mucins; it is essential for normal airway function, particularly for proper MCC [3,7,8]. ASL epithelia contain various cell types with distinct morphologies and functions. Of the cell population in the trachea, approximately 60% are ciliated cells; these cells also retain other important roles other than coordinating ciliated movements, such as regulating ion transfer [1,9].

There are detections of over 30 diverse K^+ channels in the airway epithelia, and these K^+ channels maintain the electrochemical gradient and support lung ion and fluid homeostases [1,10–12]. A large portion of airway chloride secretion occurs through the apically located bicarbonate and chloride channels [10]. K^+ channels are involved in many vital functions in lung physiology, such as oxygen sensing, inflammatory responses, enhancing Cl^- transport, and respiratory epithelia repair [9,13]. The basolateral K^+ channel has known regulation effects on Na^+ absorption; reduced Na^+ absorption in the lung shows improvement in muco-obstructive disease. A large portion of airway chloride secretion occurs through the apically located bicarbonate and chloride channels, significantly influenced by some Ca^{2+} -activated K^+ channels (K_{Ca}) that are located apically in the lung [10]. Hence, the specific K^+ group K_{Ca} also regulates MCC and ASL volumes [1]. The small-conductance K_{Ca2} channels and intermediate-conductance $K_{Ca3.1}$ channels are voltage-independent and activated solely by the elevation of the intracellular Ca^{2+} concentration. In this context, we will discuss current knowledge of the functional roles of K_{Ca2} and $K_{Ca3.1}$ channels in the respiratory tract, focusing on their physiological roles in respiratory diseases.

2. Introduction to K_{Ca} Channels

There are several kinds of K^+ channels present in the respiratory epithelium lining airways, and the most indispensable K^+ channels in airway epithelial cells are the Ca^{2+} -activated K^+ channels. They serve as the cell crossroad where Ca^{2+} influx, other ion outfluxes, and membrane potential, all processes governed by K_{Ca} channels, integrate to modulate an extensive array of cellular processes [14]. K_{Ca} channels are subdivided into three major groups, according to their single-channel conductance: large conductance (150–300 pS) K^+ channels (BK or $K_{Ca1.1}$), small conductance (2–20 pS) K^+ channels (SK or K_{Ca2}), and intermediate conductance (20–60 pS) K^+ channels (IK or $K_{Ca3.1}$) [15–17]. Each group has specific distinct biophysical and pharmacological properties [18]. $K_{Ca2.x}$ and $K_{Ca3.1}$ channels are voltage-independent and activated exclusively by intracellular Ca^{2+} via the calmodulin (CaM) that is typically bound to these channels and serves as their Ca^{2+} sensor [19]. K_{Ca2x} and $K_{Ca3.1}$ channels, before their cloning, were referred to as small-conductance (SK) or intermediate-conductance (IK) Ca^{2+} -activated K^+ channels, based on their singular conductance of ~10 pS or ~40 pS in symmetrical solutions to differentiate them from the large-conductance potassium (BK) channel [19,20].

Four mammalian KCNN channel subtypes are encoded by the KCNN genes, including KCNN1 for $K_{Ca2.1}$, KCNN2 for $K_{Ca2.2}$, KCNN3 for $K_{Ca2.3}$ [21], and KCNN4 for $K_{Ca3.1}$ [22], respectively [23] (Table 1).

Table 1. Apparent Ca^{2+} sensitivity, structural studies, amino acid sequences alignments and identities between $K_{Ca2/3}$ channel subtypes.

$K_{Ca2/3}$ α Subunit	Amino Acids	Apparent Ca^{2+} Sensitivity (μ M)	K_{Ca2} Subtypes Structural Studies	Sequence Alignment among K_{Ca2} and $K_{Ca3.1}$ Channels
$K_{Ca2.1}$	543 [24]	~0.31 [25,26]	[27,28]	$K_{Ca2.1}$ and $K_{Ca3.1}$ share a 43.3% sequence identity [29]
$K_{Ca2.2}$	579 [25]	~0.32 [25,30]	[15,26,29,31]	$K_{Ca2.2}$ and $K_{Ca3.1}$ share a 45% sequence identity [32]
$K_{Ca2.3}$	731 [25]	~0.30 [33,34]	[34,35]	$K_{Ca2.3}$ and $K_{Ca3.1}$ share a 46.6% sequence identity [34]
$K_{Ca3.1}$	427 [25]	~0.27 [33,34]	[36]	

K_{Ca2} and $K_{Ca3.1}$ Channel Structures

K_{Ca2} and $K_{Ca3.1}$ channels are assembled as homotetramers of four α -subunits; each subunit is composed of six transmembrane α -helical domains denoted as S1–S6 (Figure 1). The selectivity filter within the channel pore between the S5 and S6 transmembrane domains is responsible for the selective permeability of the K^+ ions [30,34]. The $K_{Ca2}/K_{Ca3.1}$ channel subtypes are highly homologous in their six transmembrane domains, but the amino acid

sequences and lengths at their cytoplasmic N- and C-termini differ among the subtypes (Table 1) [37].




Figure 1. $K_{Ca}3.1$ and $K_{Ca}2$ Channel Structures in the presence and absence of Ca^{2+} . $K_{Ca}2$ and $K_{Ca}3.1$ channels are assembled as homotetramers of four α -subunits. (A) Human $K_{Ca}3.1$ channel cryo-EM structure (PDB: 6cnn). For clarity, four-channel subunits are shown in different colors: green, blue, yellow, and purple, along with calmodulin (CaM) (gray). (B) Schematic representation of one channel subunit in the absence of Ca^{2+} . (C) Schematic representation of one channel subunit in the presence of Ca^{2+} . (D) Extracellular top view of the $K_{Ca}3.1$ and $K_{Ca}2$ channels. (A) was generated using Biorender.com. (B,C) were generated using Pymol (Schrödinger, LLC, New York, NY, USA).

Among the four $K_{Ca}2/K_{Ca}3.1$ channel subtypes, the full-length cryogenic electron microscopy (cryo-EM) structure is only available for the $K_{Ca}3.1$ channel determined in the absence and presence of Ca^{2+} , providing insight into the Ca^{2+}/CaM gating mechanism for these channels [36]. The calmodulin-binding domain consists of two α -helices, HA and HB, whereas the S4–S5 linker includes two α -helices, S₄₅A and S₄₅B. The HA and HB helices from one channel subunit, the S4–S5 linker from a neighboring channel subunit, and calmodulin closely interact with each other (Figure 1). When Ca^{2+} is absent, the C-lobe of CaM binds to the HA/HB helices in the proximal channel C-terminus, the N-lobe of CaM is highly flexible, and the channel pore is closed (Figure 1B). In the presence of Ca^{2+} , the N-lobe of CaM becomes well-structured and interacts with the linker between the S4 and S5 transmembrane domains (S4–S5 linker) of a neighboring α -subunit. The interaction between the Ca^{2+} -bound CaM N-lobe and the S4–S5 linker causes the movement of the S6 transmembrane domain and the opening of the channel pore (Figure 1C) [33,38].

$K_{Ca}2$ channels are activated by Ca^{2+} , with EC_{50} values ranging from 300 to 750 nM, whereas $K_{Ca}3.1$ channels exhibit apparent Ca^{2+} sensitivities of 100–400 nM [29,34,39]. $K_{Ca}2$ and $K_{Ca}3.1$ channels, therefore, play a critical role in the physiologies of various tissues and disease states [22,40]. The advances in understanding the $K_{Ca}3.1$ structure [36] (the cryo-electron microscopy of the human homotetrameric *KCNN4* channel) and the resulting improvements in other $K_{Ca}2$ subtypes modeling [29,30,34] have yet to be used, not only for drug discovery but also for understanding the pathophysiological diseases.

3. K_{Ca} Channels in the Respiratory System

The involvement of K^+ channels has been proposed in respiratory conditions such as asthma, chronic obstructive pulmonary diseases (COPD), and cystic fibrosis (CF) [1,12]. In airway epithelial cells, both Cl^- and K^+ transports rely, to some extent, on Ca^{2+} -dependent channel activity (e.g., K_{Ca} channels) [1]. K_{Ca} channels are important in regulating Cl^-

secretion, MCC, and ASL volumes. $K_{Ca}3.1$ and $K_{Ca}2$ channel subtypes located in the airway epithelia, such as $K_{Ca}2.1$ [41] and $K_{Ca}2.3$ [42], maintain the electrochemical gradient and thus support lung ion and fluid homeostasis [1]. Table 2 summarizes the *KCNN* gene family, tissue distribution, physiological roles, and their roles in the lungs.

Table 2. The *KCNN* gene family. Human chromosomal location, tissue distribution, functional effects, and their roles in the lungs.

$K_{Ca}2/3$ α Subunit	Gene	Other Names	Human Chromosomal Location	Tissue Distribution	Physiological Roles	Role in the Lungs
$K_{Ca}2.1$	<i>KCNN1</i>	SK1	19p13.11 [25]	Brain [25] Heart [43] Lung [41]	The $K_{Ca}2$ channels underlie the medium AHP and regulate neuronal firing frequency [23,44].	ND *
$K_{Ca}2.2$	<i>KCNN2</i>	SK2	5q22.3 [25]	Brain and heart Adrenal gland, lungs, prostate, bladder, and liver [25,45].		ND *
$K_{Ca}2.3$	<i>KCNN3</i>	SK3	1q21.3 [25]	Brain and heart Vascular endothelium, lungs, and bladder [25,44]	$K_{Ca}2.3$ and $K_{Ca}3.1$ mediate the endothelium-derived hyperpolarization response [33,46]	(+) $K_{Ca}2.3$ relaxes the pulmonary arteries and bronchi ** [32]
$K_{Ca}3.1$	<i>KCNN4</i>	SK4 IK	19q13.31 [25]	Vascular endothelium T and B lymphocytes Microglia, placenta, colon, and red blood cells Lungs and bladder [25,44]	$K_{Ca}3.1$ channels regulate calcium signaling, cellular activation, and cell volume [23,44]	(−) $K_{Ca}3.1$ reduces Na^+ absorption ***, (+) CBF, and MCC [5]. (+) $K_{Ca}3.1$ relaxes the pulmonary arteries and bronchi [42]

* ND: not determined specifically in the respiratory system. ** (+): Activation. *** (−): Inhibition.

3.1. K_{Ca} Channels and the Respiratory Cilia

The $K_{Ca}2$ and $K_{Ca}3.1$ channels are tetramers, and each subunit comprises six transmembrane alpha-helical domains (six TMD), indicated as S1–S6 in each channel subunit. The selectivity of potassium ions across these channels is based on the pore-forming P-loop between the transmembrane S5 and S6 domains. $K_{Ca}2/K_{Ca}3.1$ are more sensitive to Ca^{2+} due to calmodulin CaM acting as a Ca^{2+} sensor (Figure 1) [26,47]. CaM is present in all eukaryotic cells, facilitating various cellular signaling processes, such as the modulation of ion channel actions, regulation of enzymatic activities, and gene expression [14,48]. The ciliary beat of the airway epithelium is believed to be regulated by the level of intracellular Ca^{2+} [49]. The association with calmodulin in the regulation of ciliary beats has been reported as the most important intraciliary Ca^{2+} binding protein [49,50]. Moreover, the activation of $K_{Ca}2$ channels in non-excitabile cells, such as epithelial cells, increases Ca^{2+} entry through non-voltage-gated Ca^{2+} channels, thereby increasing intracellular Ca^{2+} concentration [51]. This elevation of intracellular Ca^{2+} is one of the primary regulators of ciliary movement [52]. Thus, $K_{Ca}2$ and $K_{Ca}3.1$ channels will regulate respiratory ciliary activities as part of a complex signaling network.

3.1.1. K_{Ca} Channels and Ciliary Beat Frequency

In vitro measurements of the changes in the CBF of human respiratory cells indicate that Ca^{2+} ionophore speeds the CBF of human respiratory cells mediated through a calmodulin-sensitive system [53]. Airway epithelial cells contain 100 nM of free Ca^{2+} in their cytoplasm, but ciliated cells bear a higher concentration at baseline than club cells [54]. This supports the idea that $K_{Ca}2$ channels may be active during normal conditions in specific airway cells, as these channels show a high sensitivity to Ca^{2+} (Table 2). Significantly, in CF mouse airways, a previous study by Vega et al. [5] determined that *KCNN4*-silencing enhanced MCC when Na^+ absorption was decreased. Additionally, CBF was also increased by $K_{Ca}3.1$ inhibition. An explanation is that $K_{Ca}3.1$ inhibition reduces Na^+ absorption in CF, thereby increasing CBF speeds by hyperpolarizing the apical membrane [5,55].

3.1.2. K_{Ca2} Channels and Cilium Length

Muco-obstructive lung disease is considered the primary cause of morbidity and is responsible for 80% of mortality [55]. The presence of K_{Ca2} channels in a human bronchial epithelial cell, and structural similarities in the groups of K_{Ca2} and $K_{Ca3.1}$, provides a new direction in the investigating the expression and function of K_{Ca2} channel subtypes in the ciliated human lung epithelial cells. Optimal MCC requires mucus, cilia, and a thin layer of ASL to facilitate ciliary beating [2]. Maintaining a normal range of respiratory cilia length (4 to 7 μm , depending on the airway region) is critical for adequate mucociliary clearance [56]. A qualitative difference exists between short and longer cilia waveform shapes [57], and various acquired lung disorders are marked by abnormalities in both cilia structure and function [56]. Our previous work determined the critical role of $K_{Ca2.3}$ channels in regulating the primary cilia in endothelial cells [58]. Taking advantage of the previous results could help to connect K_{Ca2} channels and respiratory cilia, two crucial components in the Ca^{2+} signaling network of airway epithelial and smooth muscle cells, with potential implications in the pathogenesis of airway diseases.

4. Expression and Physiological Functions of K_{Ca2} and $K_{Ca3.1}$ Channels in the Airways

Many human cells express K_{Ca} channels that have the exceptional ability to translate changes in the level of the intracellular second messenger, Ca^{2+} , to changes in membrane K^+ conductance and, thus, resting potential membrane. While K_{Ca} channel subtypes are all regulated by intracellular Ca^{2+} , they are otherwise quite distinct entities, differing in tissue distribution and functions [59]. K_{Ca2} channel subtypes, for example, are widely expressed in the nervous system, where they are involved in regulating the firing frequency of various neurons. On the other hand, the $K_{Ca3.1}$ channel subtype is expressed in peripheral cells, including the erythrocytes and lymphocytes, and has been determined in numerous cancer cells where they have been implicated in growth control [60,61]. Here we demonstrate the expressions and physiological roles of K_{Ca2} and $K_{Ca3.1}$ channels in the airways.

4.1. Expression and Functions of K_{Ca2} in the Respiratory Epithelia

K_{Ca2} channels are widely expressed in various tissues and play an important role in modulating excitable and non-excitable cells. The presence of K_{Ca} channel groups was confirmed at the apical and basolateral membranes of airway epithelial cells [1,62] (Figure 2A). The bronchial epithelium expresses $K_{Ca2.1}$ and $K_{Ca2.3}$ channel subtypes [35,41]. $K_{Ca2.2}$ and $K_{Ca2.3}$ mRNA were detected in the lungs and trachea [3,4]. $K_{Ca2.2}$ and $K_{Ca2.3}$ mRNA were detected in lungs and trachea [6]. $K_{Ca2.3}$ is the only subtype expressed in the pulmonary artery [5]. Figure 2-B shows the major expression sites of K_{Ca2} and $K_{Ca3.1}$ channel subtypes in the airway.

Different ion channels seem to be present in motile cilia [63]. In the nasal cavity, olfactory receptor neurons (ORNs) are adapted to grow various long cilia; they are not motile but can move with the liquid stream of the nasal mucosa to sample odorants entering the nose. The presence of K_{Ca} channel groups in the cilia of ORNs was reported [64].

The involvement of K^+ channels has been proposed in respiratory conditions such as asthma, chronic obstructive pulmonary diseases (COPD), and cystic fibrosis (CF) [1,12]. In airway epithelial cells, both Cl^- and K^+ transports rely, to some extent, on Ca^{2+} -dependent channel activity (e.g., K_{Ca} channels) [1]. K_{Ca} channels are important in regulating Cl^- secretion, MCC, and ASL volumes. K_{Ca2} channel subtypes located in the airway epithelia, such as $K_{Ca2.1}$ [41] and $K_{Ca2.3}$ [42], maintain the electrochemical gradient and thus support lung ion and fluid homeostases [1].




Figure 2. Expression sites of $K_{Ca}2$ and $K_{Ca}3.1$ channels in the respiratory system. (A) Schematic drawing of ciliated airway epithelial cells of $K_{Ca}2$ and $K_{Ca}3.1$ channels. (B) $K_{Ca}2$ and $K_{Ca}3.1$ channels were expressed in airway smooth muscle [65], airway olfactory nerves [66] and olfactory cilia [64]; $K_{Ca}2.2$ and $K_{Ca}2.3$ subtypes presented in the lungs and the trachea [45]; and $K_{Ca}3.1$, $K_{Ca}2.1$, and $K_{Ca}2.3$ subtypes presented in the respiratory epithelia [41,42]. The pulmonary artery expressed the $K_{Ca}2.3$ subtype [42].

In CF, the equilibrium between Na^+ absorption and Cl^- secretion throughout the airway epithelia is necessary to maintain adequate ASL volume and MCC. The Cl^- secretion in the lungs involves several steps, starting from Cl^- entry through a basolateral channel cotransporter, followed by its exit via apical Cl^- channels, such as the cystic fibrosis transmembrane conductance regulator (CFTR) [3]. The dysfunction of CFTR channels in CF results in decreased Cl^- and fluid secretions and increased Na^+ absorption, leading to inefficient mucociliary clearance and mucus accumulation [67].

In COPD, K_{Ca} channel groups can also act as oxygen sensors for lung diseases, such as COPD associated with pulmonary hypertension [12]. In COPD, pulmonary hypertension is generally believed to be due to hypoxic pulmonary vasoconstriction [68]. K_{Ca} channels potentiated by the low partial pressure of oxygen (PO_2) have been investigated in cerebral resistance myocytes [69]. When hypoxia occurs, K_{Ca} channels activate (preventing repolarization) and relax the pulmonary arteries [70,71].

K_{Ca} channels were proposed as new targets for bronchodilator therapy for chronic diseases such as asthma and COPD [72]. The mentioned COPD-related studies [69–72] examined K_{Ca} channel groups in general. Though one study suggested that human pulmonary artery and bronchial relaxations might be mediated by pharmacological activation of the $K_{Ca}2.3$ channel subtypes [42] (Table 2).

In anosmia, Odorant-induced K^+ conductance is activated by Ca^{2+} [73], and the elevation of intracellular Ca^{2+} is often associated with odorant stimulation in some vertebrates and human olfactory neurons [51,74]. Olfactory Receptor Neurons (ORNs) are located in the nasal epithelia and exhibit spontaneous action potential firing. All K_{Ca} channel groups have been detected in olfactory cilia [52], and the electrophysiological of the whole-cell results confirmed that K_{Ca} channels participate in inhibitory chemo-transduction in the cilia [75]. According to these findings, an apical Ca^{2+} influx opens the K_{Ca} channels, causing membrane hyperpolarization in response to Ca^{2+} influx and thus triggering the inhibition [74].

Moreover, a Ca^{2+} channel blocker, nifedipine, was tested on odorants that induce an inhibitory current in olfactory neurons [74]. This drug effectively abolished the outward current and stimulated the cells with an odorant solution free of nifedipine, and the response was restored [74]. $K_{Ca}2$ channel subtypes which are completely Ca^{2+} -dependent and voltage-independent may play a critical role in treating certain diseases, given the drugs that could target specific ion channels. For example, anosmia could be treated by targeting the $K_{Ca}2$ channel subtypes in olfactory cilia and testing their allosteric modulators [52]. However, the pharmacology of these channels in olfactory neurons has not been fully characterized.

4.2. Expression and Functions of $K_{Ca}3.1$ in the Respiratory Epithelia

The expression of Ca^{2+} -activated potassium (K_{Ca}) channels often correlate positively with cell proliferation. As an example, the expression of $K_{Ca}3.1$ increases 4-fold upon T-lymphocyte activation, and this channel is inhibited with the specific inhibitor that inhibits T-lymphocyte proliferation [76]. This is because the $K_{Ca}3.1$ channel contributes to electrochemical gradients for Ca^{2+} influx, which is critical for the proliferation of the T cells [77]. $K_{Ca}3.1$ is also broadly expressed in other cells of the immune system, such as B cells, macrophages, microglia, and mast cells [78]. The major function of $K_{Ca}3.1$ in immune cells is to hyperpolarize the cell membrane and create the driving force for calcium entry, which is necessary for proliferation, activation, and cytokine production [79]. Previous findings [80] suggest that antigen sensitization up-regulates $K_{Ca}3.1$ expression, which may contribute to enhancing cell migration in response to lymphatic chemokines, particularly in the immunogenic lung dendritic cells subset. Therefore, targeting $K_{Ca}3.1$ crucial for controlling allergic airway inflammation [81] (Table 2 and Figure 2).

K_{Ca} channels have been found to be involved in regulating smooth muscle responses to both contractile and relaxant agonists that elevate intracellular Ca^{2+} [82]. Phenotypic modulation of smooth muscle cells is accompanied by changes in $K_{Ca}3.1$ channel expression characterizing “proliferative” cells [83]. $K_{Ca}3.1$ channels regulate the proliferative responses of vascular smooth muscle cells, fibroblasts, endothelial cells, and T lymphocytes, as well as some transformed cell types [61,84]. $K_{Ca}3.1$ function is increased by protein kinase A (PKA) [85] and nucleoside diphosphate kinase B (NDPK-B) and inhibited by the histidine phosphatase PHPT1 [86,87]. Since NDPK-B and PHPT1 directly phosphorylate or dephosphorylate $K_{Ca}3.1$ on histidine in the C-terminus, $K_{Ca}3.1$ modulation in mammals is one of the rare examples of histidine kinase/phosphatase regulating a biological process [86].

In allergic lung diseases, $K_{Ca}3.1$ channels regulate Ca^{2+} entry into cells and thereby modulate Ca^{2+} -signaling processes. The entry of positively charged Ca^{2+} into the cells depolarizes the membrane, which limits its own ability to enter the cell through some types of Ca^{2+} channels that are closed at more positive membrane potentials. $K_{Ca}3.1$ activation by elevated intracellular Ca^{2+} maintains a negative membrane potential, which helps to sustain Ca^{2+} entry into the cell. $K_{Ca}3.1$ -mediated elevation of intracellular Ca^{2+} is necessary for the production of inflammatory chemokines and cytokines by T cells, mast cells, and macrophages [79,88]. Indeed, proliferation is accompanied by the transcriptional up-regulation of functional $K_{Ca}3.1$ expression and can be inhibited by $K_{Ca}3.1$ inhibitors [86]. It has been reported that the use of $K_{Ca}3.1$ blockers can provide a potential therapeutic target for mast cell-mediated diseases such as asthma [88]. Moreover, blocking $K_{Ca}3.1$ may offer a novel approach to treating idiopathic pulmonary fibrosis [89].

In muco-obstructive hyper tension, the inhibition of the $K_{Ca}3.1$ channel [5] and *Kcnn4* silencing in ion transport and MCC in an animal model of CF/COPD-like muco-obstructive lung disease determined that *Kcnn4* silencing enhances airway disease [5]. The effectiveness of the mucociliary clearance depends mainly on hydration. Water availability in the airways is controlled by transepithelial ion transport. Apical Cl^{-} secretion and Na^{+} absorption play major roles in ASL volume homeostasis [90]. The decline in Na^{+} absorption is of potential benefit in muco-obstructive disorders, such as cystic fibroses. It was described earlier in the case of the kidney and intestine, where the inhibition of basolateral K^{+} channels decreased Na^{+} absorption [5,57], thus supporting the role of K^{+} channels on epithelial Na^{+} homeostasis.

In pulmonary artery hypertension, elevated pulmonary artery pressure occurs in several diseases, such as asthma, end-stage chronic obstructive pulmonary disease (COPD), and lung fibrosis [66,91,92]. In order to diagnose pulmonary artery hypertension, hemodynamic measurements are taken via right heart catheterization or echocardiography; the condition is defined as a mean pulmonary artery pressure above 25 mmHg at rest or greater than 30 mmHg during normal physical activity [92]. Studies suggest that pharma-

cologically activating $K_{Ca3.1}$ channels mediates human pulmonary artery and bronchial relaxations [42]

5. Pharmacological K_{Ca2} and $K_{Ca3.1}$ Channel Modulators in Respiratory Diseases

The $K_{Ca2.3}$ and $K_{Ca3.1}$ potassium channels are characterized by their voltage independence, and thus, they are activated by intracellular Ca^{2+} . Due to the distinct distribution of the channel subtypes in the mammalian cells and their involvement in the generation of afterhyperpolarization currents, there has been considerable interest in developing subtype-selective pharmacological tools to study these channels [93,94]. Additionally, $K_{Ca2.3}$ and $K_{Ca3.1}$ channels comprise attractive new targets for several diseases that currently have no effective therapies. The pharmacology of K_{Ca} channels developed relatively rapidly after the cloning of the K_{Ca2} and $K_{Ca3.1}$ channels, as the field now has a wide range of peptides, small-molecule inhibitors, and positive- and negative-gating modulators with differential subtype selectivity available [44].

The $K_{Ca3.1}$ and K_{Ca2} channels have relatively well-developed pharmacological tools. The field now has a wide range of peptides, small-molecule inhibitors, and positive- and negative-gating modulators with differential subtype selectivity available [93]. Table 3 shows the small molecule positive and negative modulators with differential K_{Ca2} subtype selectivity [44]. For treating CF and other mucociliary diseases, $K_{Ca3.1}$ inhibitors are needed [5]. Senicapoc [95] and TRAM-34 [96] inhibit $K_{Ca3.1}$ channels with IC_{50} values of ~11 nM, and ~20 nM, respectively, and they are highly selective for $K_{Ca3.1}$ channels over K_{Ca2} channel subtypes [33]. The selective negative modulator for the K_{Ca2} channel AP14145 is equipotent in inhibiting $K_{Ca2.2}$ and $K_{Ca2.3}$ but is ineffective on $K_{Ca3.1}$ channels [97].

For treating anosmia, COPD and its related pulmonary hypertension, K_{Ca2} -positive modulators may be beneficial [42,46,62]. NS309 is a potent, non-selective activator of human $K_{Ca3.1}$ and K_{Ca2} channels [98]. The $K_{Ca2.2}$ and $K_{Ca2.3}$ channels are potently and selectively activated by CyPPA [38], and their derivatives are chemically modified to create more efficient and selective positive modulators [99]. However, further investigations are needed to determine their effectiveness [33].

Table 3. Small-molecule positive and negative modulators of K_{Ca2} and $K_{Ca3.1}$ channels.

	Nonselective $K_{Ca2}/K_{Ca3.1}$	K_{Ca2} Selective	$K_{Ca3.1}$ Selective	Subtype K_{Ca2} Selective
Positive modulators	NS309 [98] SKA-31 [100] 1-EBIO [101] Riluzole [102]		SKA-111 [44] SKA-121 [103]	$K_{Ca2.2}/K_{Ca2.3}$ selective
				CyPPA [38] NS13001 [104] Compound 2q * [99]
				$K_{Ca2.1}$ selective
				CM-TPMF [102]
Negative modulators	RA-2 [103]	NS5893 [104] AP14145 [97]	Senicapoc [11,95] TRAM-34 [96]	$K_{Ca2.1}$ selective Bu-TPMF [102]

* 2q is a CyPPA-modified compound, other CyPPA modified compounds include: 2m–2n, 2p, 2r–2t, 2v, and 4. The potencies of these compounds on potentiating $K_{Ca2.3}$ and $K_{Ca2.2a}$ channels have previously been determined [57,99].

6. Conclusions and Perspectives

In recent years, remarkable progress has been made in understanding the physiological and pathophysiological roles of K_{Ca} channels. The advances in understanding the $K_{Ca3.1}$ structure and the resulting improvements in other K_{Ca2} subtypes modeling have yet to be used, not only for drug discovery but also for understanding the pathophysiological diseases, particularly airway diseases, and developing more subtype-selective biophysical and pharmacological tools. Over the past few years, researchers have studied $K_{Ca3.1}$ channel expression and its physiological role in airway diseases. There are, however, few studies on K_{Ca2} channels in the respiratory system. Evidence now suggests that K_{Ca2} channels are present in the respiratory system and play an important role in airway

disorders, such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, and other muco-obstructive diseases. Nevertheless, further studies are necessary to unveil the exact cell distribution, subcellular localization, and protein interactions of $K_{Ca}2$ channels in the airways. Additional research is required to further establish and validate $K_{Ca}2$ and $K_{Ca}3.1$ channels as ion channels in airway diseases, their clinical relevance, and the development of more potent and subtype selective $K_{Ca}2$ channel modulators.

Author Contributions: R.O. drafted the manuscript; A.A., M.A.R. and L.L. edited and revised the manuscript; Y.-W.N. and M.Z. approved the final version of the manuscript. All authors contributed to the manuscript and the figures. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by a 23AIREA1039423 grant from the American Heart Association, a YI-SCA grant from the National Ataxia Foundation, and a 4R33NS101182-03 grant from NIH awarded to M.Z. And grant 023-012 from King Fahad Medical City Research Center awarded to R.O.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We thank King Fahad Medical City Research Center and Chapman University Writing Center for revising the manuscript. We thank Fan Feng and Reem Orfali for their technical support. Figures were created with BioRender and published with permission.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

ASL	Airway surface liquid
Ca^{2+}	Calcium
CaM	Calmodulin
Cl^{-}	Chloride
COPD	Chronic obstructive pulmonary disease
CBF	Cilia beating frequency
K_{Ca}	Ca^{2+} -activated K^{+} channels
CF	Cystic fibrosis
CFTR	Cystic fibrosis transmembrane conductance regulator
$K_{Ca}3.1$	Intermediate-conductance Ca^{2+} -activated K^{+} channels
BK	Large-conductance Ca^{2+} -activated K^{+} channels
MCC	Mucociliary clearance
ORNs	Olfactory receptor neurons
K^{+}	Potassium
$K_{Ca}2$	Small-conductance Ca^{2+} -activated K^{+} channels
Na^{+}	Sodium
TMs	Transmembrane helices
WT	Wild type

References

1. Bartoszewski, R.; Matalon, S.; Collawn, J.F. Ion channels of the lung and their role in disease pathogenesis. *Am. J. Physiol. Cell. Mol. Physiol.* **2017**, *313*, L859–L872. [[CrossRef](#)] [[PubMed](#)]
2. Mall, M.A. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: Lessons from mouse models. *J. Aerosol. Med. Pulm. Drug Deliv.* **2008**, *21*, 13–24. [[CrossRef](#)] [[PubMed](#)]
3. Munkholm, M.; Mortensen, J. Mucociliary clearance: Pathophysiological aspects. *Clin. Physiol. Funct. Imaging* **2014**, *34*, 171–177. [[CrossRef](#)]
4. Bhowmik, A.; Chahal, K.; Austin, G.; Chakravorty, I. Improving mucociliary clearance in chronic obstructive pulmonary disease. *Respir. Med.* **2009**, *103*, 496–502. [[CrossRef](#)]
5. Vega, G.; Guequén, A.; Philp, A.R.; Gianotti, A.; Arzola, L.; Villalón, M.; Zegarra-Moran, O.; Galiotta, L.J.; Mall, M.A.; Flores, C.A. Lack of *Kcnn4* improves mucociliary clearance in muco-obstructive lung disease. *JCI Insight* **2020**, *5*, 140076. [[CrossRef](#)] [[PubMed](#)]
6. Roy, M.G.; Livraghi-Butrico, A.; Fletcher, A.A.; McElwee, M.M.; Evans, S.E.; Boerner, R.M.; Alexander, S.N.; Bellinghausen, L.K.; Song, A.S.; Petrova, Y.M.; et al. *Muc5b* is required for airway defence. *Nature* **2014**, *505*, 412–416. [[CrossRef](#)]

7. Spina, D. Epithelium smooth muscle regulation and interactions. *Am. J. Respir. Crit. Care Med.* **1998**, *158*, S141–S145. [[CrossRef](#)]
8. Callaghan, P.J.; Ferrick, B.; Rybakovsky, E.; Thomas, S.; Mullin, J.M. Epithelial barrier function properties of the 16HBE14o-human bronchial epithelial cell culture model. *Biosci. Rep.* **2020**, *40*, BSR20201532. [[CrossRef](#)]
9. Hollenhorst, M.I.; Richter, K.; Fronius, M. Ion transport by pulmonary epithelia. *J. Biomed. Biotechnol.* **2011**, *2011*, 174306. [[CrossRef](#)]
10. Bernard, K.; Bogliolo, S.; Soriani, O.; Ehrenfeld, J. Modulation of calcium-dependent chloride secretion by basolateral SK4-like channels in a human bronchial cell line. *J. Membr. Biol.* **2003**, *196*, 15–31. [[CrossRef](#)]
11. Staal, R.G.W.; Weinstein, J.R.; Nattini, M.; Cajina, M.; Chandresana, G.; Möller, T. Senicapoc: Repurposing a Drug to Target Microglia $K_{Ca}3.1$ in Stroke. *Neurochem. Res.* **2017**, *42*, 2639–2645. [[CrossRef](#)]
12. Bardou, O.; Trinh, N.T.N.; Brochiero, E. Molecular diversity and function of K^+ channels in airway and alveolar epithelial cells. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2009**, *296*, L145–L155. [[CrossRef](#)] [[PubMed](#)]
13. $KCa3.1$ Channel Blockade Attenuates Microvascular Remodelling in a Large Animal Model of Bleomycin-Induced Pulmonary Fibrosis | Scientific Reports n.d. Available online: <https://www.nature.com/articles/s41598-019-56412-z> (accessed on 15 March 2023).
14. Zühlke, R.D.; Pitt, G.S.; Deisseroth, K.; Tsien, R.W.; Reuter, H. Calmodulin supports both inactivation and facilitation of L-type calcium channels. *Nature* **1999**, *399*, 159–162. [[CrossRef](#)] [[PubMed](#)]
15. Nam, Y.-W.; Orfali, R.; Liu, T.; Yu, K.; Cui, M.; Wulff, H.; Zhang, M. Structural insights into the potency of SK channel positive modulators. *Sci. Rep.* **2017**, *7*, 17178. [[CrossRef](#)]
16. [PDF] Unstructured to Structured Transition of an Intrinsically Disordered Protein Peptide in Coupling Ca^{2+} -Sensing and SK Channel Activation | Semantic Scholar n.d. Available online: <https://www.semanticscholar.org/paper/Unstructured-to-structured-transition-of-an-protein-Zhang-Pascal/9f5cff1624625aaab67cab5639813dba6db10b4> (accessed on 15 March 2023).
17. Catacuzzeno, L.; Fioretti, B.; Franciolini, F. Expression and Role of the Intermediate-Conductance Calcium-Activated Potassium Channel $KCa3.1$ in Glioblastoma. *J. Signal. Transduct.* **2012**, *2012*, 421564. [[CrossRef](#)] [[PubMed](#)]
18. Jensen, B.S.; Strøbaek, D.; Olesen, S.P.; Christophersen, P. The Ca^{2+} -activated K^+ channel of intermediate conductance: A molecular target for novel treatments? *Curr. Drug. Targets* **2001**, *2*, 401–422. [[CrossRef](#)]
19. Kaczmarek, L.K.; Aldrich, R.W.; Chandy, K.G.; Grissmer, S.; Wei, A.D.; Wulff, H. International Union of Basic and Clinical Pharmacology. C. Nomenclature and Properties of Calcium-Activated and Sodium-Activated Potassium Channels. *Pharmacol. Rev.* **2017**, *69*, 1–11. [[CrossRef](#)]
20. Christophersen, P.; Wulff, H. Pharmacological gating modulation of small- and intermediate-conductance Ca^{2+} -activated K^+ channels ($K_{Ca2.x}$ and $K_{Ca3.1}$). *Channels* **2015**, *9*, 336–343. [[CrossRef](#)]
21. Padula, A.E.; Griffin, W.C.; Lopez, M.F.; Nimitvilai, S.; Cannady, R.; McGuier, N.S.; Chesler, E.J.; Miles, M.F.; Williams, R.W.; Randall, P.K.; et al. KCNN Genes that Encode Small-Conductance Ca^{2+} -Activated K^+ Channels Influence Alcohol and Drug Addiction. *Neuropsychopharmacol* **2015**, *40*, 1928–1939. [[CrossRef](#)] [[PubMed](#)]
22. Begenisich, T.; Nakamoto, T.; Ovitt, C.E.; Nehrke, K.; Brugnara, C.; Alper, S.L.; Melvin, J.E. Physiological Roles of the Intermediate Conductance, Ca^{2+} -activated Potassium Channel $Kcnn4^*$. *J. Biol. Chem.* **2004**, *279*, 47681–47687. [[CrossRef](#)]
23. Orfali, R.; Albanyan, N. Ca^{2+} -Sensitive Potassium Channels. *Molecules* **2023**, *28*, 885. [[CrossRef](#)] [[PubMed](#)]
24. Girault, A.; Haelters, J.-P.; Potier-Cartereau, M.; Chantôme, A.; Jaffrés, P.-A.; Bougnoux, P.; Joulin, V.; Vandier, C. Targeting SKCa channels in cancer: Potential new therapeutic approaches. *Curr. Med. Chem.* **2012**, *19*, 697–713. [[CrossRef](#)]
25. Aldrich, R.; Chandy, K.G.; Grissmer, S.; Gutman, G.A.; Kaczmarek, L.K.; Wei, A.D.; Wulff, H. Calcium- and sodium-activated potassium channels (K_{Ca} , K_{Na}) in GtoPdb v.2021.3. *GtoPdb CITE* **2021**, *2021*. [[CrossRef](#)]
26. Xia, X.-M.; Fakler, B.; Rivard, A.; Wayman, G.; Johnson-Pais, T.; Keen, J.E.; Ishii, T.; Hirschberg, B.; Bond, C.T.; Lutsenko, S.; et al. Mechanism of calcium gating in small-conductance calcium-activated potassium channels. *Nature* **1998**, *395*, 503–507. [[CrossRef](#)] [[PubMed](#)]
27. Shmukler, B.E.; Bond, C.T.; Wilhelm, S.; Bruening-Wright, A.; Maylie, J.; Adelman, J.P.; Alper, S.L. Structure and complex transcription pattern of the mouse SK1 K_{Ca} channel gene, KCNN1. *Biochim. Biophys. Acta* **2001**, *1518*, 36–46. [[CrossRef](#)] [[PubMed](#)]
28. Zhang, B.M.; Kohli, V.; Adachi, R.; López, J.A.; Udden, M.M.; Sullivan, R. Calmodulin binding to the C-terminus of the small-conductance Ca^{2+} -activated K^+ channel hSK1 is affected by alternative splicing. *Biochemistry* **2001**, *40*, 3189–3195. [[CrossRef](#)]
29. Nam, Y.-W.; Cui, M.; El-Sayed, N.S.; Orfali, R.; Nguyen, M.; Yang, G.; Rahman, M.A.; Lee, J.; Zhang, M. Subtype-selective positive modulation of $KCa2$ channels depends on the HA/HB helices. *Br. J. Pharmacol.* **2022**, *179*, 460–472. [[CrossRef](#)] [[PubMed](#)]
30. Nam, Y.-W.; Cui, M.; Orfali, R.; Viegas, A.; Nguyen, M.; Mohammed, E.H.M.; Zoghebi, K.A.; Rahighi, S.; Parang, K.; Zhang, M. Hydrophobic interactions between the HA helix and S4-S5 linker modulate apparent Ca^{2+} sensitivity of SK2 channels. *Acta Physiol.* **2021**, *231*, e13552. [[CrossRef](#)]
31. El-Sayed, N.S.; Nam, Y.-W.; Egorova, P.A.; Nguyen, H.M.; Orfali, R.; Rahman, M.A.; Yang, G.; Wulff, H.; Bezprozvanny, I.; Parang, K.; et al. Structure-Activity Relationship Study of Subtype-Selective Positive Modulators of $KCa2$ Channels. *J. Med. Chem.* **2022**, *65*, 303–322. [[CrossRef](#)]
32. Morales, P.; Garneau, L.; Klein, H.; Lavoie, M.-F.; Parent, L.; Sauvé, R. Contribution of the $KCa3.1$ channel–calmodulin interactions to the regulation of the $KCa3.1$ gating process. *J. Gen. Physiol.* **2013**, *142*, 37–60. [[CrossRef](#)] [[PubMed](#)]
33. Nam, Y.-W.; Downey, M.; Rahman, M.A.; Cui, M.; Zhang, M. Channelopathy of small- and intermediate-conductance Ca^{2+} -activated K^+ channels. *Acta Pharmacol. Sin.* **2023**, *44*, 259–267. [[CrossRef](#)]

34. Orfali, R.; Nam, Y.-W.; Nguyen, H.M.; Rahman, M.A.; Yang, G.; Cui, M.; Wulff, H.; Zhang, M. Channelopathy-causing mutations in the S45A/S45B and HA/HB helices of $K_{Ca}2.3$ and $K_{Ca}3.1$ channels alter their apparent Ca^{2+} sensitivity. *Cell Calcium* **2022**, *102*, 102538. [[CrossRef](#)] [[PubMed](#)]
35. Monaghan, A.S.; Benton, D.C.H.; Bahia, P.K.; Hosseini, R.; Shah, Y.A.; Haylett, D.G.; Moss, G.W.J. The SK3 Subunit of Small Conductance Ca^{2+} -activated K^+ Channels Interacts with Both SK1 and SK2 Subunits in a Heterologous Expression System. *J. Biol. Chem.* **2004**, *279*, 1003–1009. [[CrossRef](#)] [[PubMed](#)]
36. Lee, C.-H.; MacKinnon, R. Activation mechanism of a human SK-calmodulin channel complex elucidated by cryo-EM structures. *Science* **2018**, *360*, 508–513. [[CrossRef](#)] [[PubMed](#)]
37. Ishii, T.M.; Silvia, C.; Hirschberg, B.; Bond, C.T.; Adelman, J.P.; Maylie, J. A human intermediate conductance calcium-activated potassium channel. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 11651–11656. [[CrossRef](#)] [[PubMed](#)]
38. Hougaard, C.; Eriksen, B.L.; Jørgensen, S.; Johansen, T.H.; Dyhring, T.; Madsen, L.S.; Strøbaek, D.; Christophersen, P. Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca^{2+} -activated K^+ channels. *Br. J. Pharmacol.* **2007**, *151*, 655–665. [[CrossRef](#)] [[PubMed](#)]
39. Orfali, R. Genetic Mutations of $K_{Ca}2.3$ and $K_{Ca}3.1$ Channels Affect Ca^{2+} Sensitivity. Ph.D. Thesis, Pharmaceutical Sciences, Chapman University, Irvine, CA, USA, 2023. [[CrossRef](#)]
40. Wulff, H.; Zhorov, B.S. K^+ Channel Modulators for the Treatment of Neurological Disorders and Autoimmune Diseases. *Chem. Rev.* **2008**, *108*, 1744–1773. [[CrossRef](#)] [[PubMed](#)]
41. Bardou, O.; Trinh, N.T.N.; Brochiero, E. Canaux potassiques et physiologie de l'épithélium respiratoire. *Med. Sci.* **2009**, *25*, 391–397. [[CrossRef](#)]
42. Kroigaard, C.; Dalsgaard, T.; Nielsen, G.; Laursen, B.E.; Pilegaard, H.; Köhler, R.; Simonsen, U. Activation of endothelial and epithelial $K_{Ca}2.3$ calcium-activated potassium channels by NS309 relaxes human small pulmonary arteries and bronchioles. *Br. J. Pharmacol.* **2012**, *167*, 37–47. [[CrossRef](#)] [[PubMed](#)]
43. Rahm, A.; Wieder, T.; Gramlich, D.; Müller, M.E.; Wunsch, M.N.; El Tahry, F.A.; Heimberger, T.; Sandke, S.; Weis, T.; Most, P.; et al. Differential regulation of $K_{Ca}2.1$ (KCNN1) K^+ channel expression by histone deacetylases in atrial fibrillation with concomitant heart failure. *Physiol. Rep.* **2021**, *9*, e14835. [[CrossRef](#)]
44. Brown, B.M.; Shim, H.; Christophersen, P.; Wulff, H. Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels. *Annu. Rev. Pharmacol. Toxicol.* **2020**, *60*, 219–240. [[CrossRef](#)] [[PubMed](#)]
45. Chen, M.X.; Gorman, S.A.; Benson, B.; Singh, K.; Hieble, J.P.; Michel, M.C.; Tate, S.N.; Trezise, D.J. Small and intermediate conductance Ca^{2+} -activated K^+ channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2004**, *369*, 602–615. [[CrossRef](#)] [[PubMed](#)]
46. Wulff, H.; Köhler, R. Endothelial Small- and Intermediate-Conductance KCa Channels: An Update on Their Pharmacology and Usefulness as Cardiovascular Targets. *J. Cardiovasc. Pharmacol.* **2013**, *61*, 102–112. [[CrossRef](#)]
47. Schumacher, M.A.; Rivard, A.F.; Bächinger, H.P.; Adelman, J.P. Structure of the gating domain of a Ca^{2+} -activated K^+ channel complexed with Ca^{2+} /calmodulin. *Nature* **2001**, *410*, 1120–1124. [[CrossRef](#)]
48. Zhang, M.; Abrams, C.; Wang, L.; Gizzi, A.; He, L.; Lin, R.; Chen, Y.; Loll, P.J.; Pascal, J.M.; Zhang, J. Structural basis for calmodulin as a dynamic calcium sensor. *Structure* **2012**, *20*, 911–923. [[CrossRef](#)]
49. Nguyen, T.N.; Suzuki, H.; Ohkubo, J.-I.; Wakasugi, T.; Kitamura, T. Calmodulin Regulates Ciliary Beats in the Human Nasal Mucosa Through Adenylate/Guanylate Cyclases and Protein Kinases A/G. *Int. Arch. Allergy Immunol.* **2021**, *182*, 800–806. [[CrossRef](#)] [[PubMed](#)]
50. Valeyev, N.V.; Bates, D.G.; Heslop-Harrison, P.; Postlethwaite, I.; Kotov, N.V. Elucidating the mechanisms of cooperative calcium-calmodulin interactions: A structural systems biology approach. *BMC Syst. Biol.* **2008**, *2*, 48. [[CrossRef](#)] [[PubMed](#)]
51. Restrepo, D.; Okada, Y.; Teeter, J.H.; Lowry, L.D.; Cowart, B.; Brand, J.G. Human olfactory neurons respond to odor stimuli with an increase in cytoplasmic Ca^{2+} . *Biophys. J.* **1993**, *64*, 1961–1966.
52. Delgado, R.; Saavedra, M.V.; Schmachtenberg, O.; Sierralta, J.; Bacigalupo, J. Presence of Ca^{2+} -dependent K^+ channels in chemosensory cilia support a role in odor transduction. *J. Neurophysiol.* **2003**, *90*, 2022–2028. [[CrossRef](#)] [[PubMed](#)]
53. Di Benedetto, G.; Magnus, C.J.; Gray, P.T.; Mehta, A. Calcium regulation of ciliary beat frequency in human respiratory epithelium in vitro. *J. Physiol.* **1991**, *439*, 103–113. [[CrossRef](#)]
54. De Proost, I.; Pintelon, I.; Brouns, I.; Kroese, A.B.A.; Riccardi, D.; Kemp, P.J.; Timmermans, J.-P.; Adriaensen, D. Functional live cell imaging of the pulmonary neuroepithelial body microenvironment. *Am. J. Respir. Cell Mol. Biol.* **2008**, *39*, 180–189. [[CrossRef](#)] [[PubMed](#)]
55. Ohba, T.; Sawada, E.; Suzuki, Y.; Yamamura, H.; Ohya, S.; Tsuda, H.; Imaizumi, Y. Enhancement of Ca^{2+} influx and ciliary beating by membrane hyperpolarization due to ATP-sensitive K^+ channel opening in mouse airway epithelial cells. *J. Pharmacol. Exp. Ther.* **2013**, *347*, 145–153. [[CrossRef](#)]
56. Tilley, A.E.; Walters, M.S.; Shaykhiev, R.; Crystal, R.G. Cilia Dysfunction in Lung Disease. *Annu. Rev. Physiol.* **2015**, *77*, 379–406. [[CrossRef](#)]
57. Hebert, S.C.; Desir, G.; Giebisch, G.; Wang, W. Molecular diversity and regulation of renal potassium channels. *Physiol. Rev.* **2005**, *85*, 319–371. [[CrossRef](#)] [[PubMed](#)]

58. Nam, Y.-W.; Pala, R.; El-Sayed, N.S.; Larin-Henriquez, D.; Amirrad, F.; Yang, G.; Rahman, M.A.; Orfali, R.; Downey, M.; Parang, K.; et al. Subtype-Selective Positive Modulation of $K_{Ca}2.3$ Channels Increases Cilia Length. *ACS Chem. Biol.* **2022**, *17*, 2344–2354. [CrossRef]
59. Weaver, A.K.; Bomben, V.C.; Sontheimer, H. Expression and Function of Calcium-Activated Potassium Channels in Human Glioma Cells. *Glia* **2006**, *54*, 223–233. [CrossRef] [PubMed]
60. Stocker, M. Ca^{2+} -activated K^{+} channels: Molecular determinants and function of the SK family. *Nat. Rev. Neurosci.* **2004**, *5*, 758–770. [CrossRef]
61. Shepherd, M.C.; Duffy, S.M.; Harris, T.; Cruse, G.; Schuliga, M.; Brightling, C.E.; Neylon, C.B.; Bradding, P.; Stewart, A.G. $K_{Ca}3.1$ Ca^{2+} Activated K^{+} Channels Regulate Human Airway Smooth Muscle Proliferation. *Am. J. Respir. Cell Mol. Biol.* **2007**, *37*, 525–531. [CrossRef]
62. Kunzelmann, K.; Pavenstädt, H.; Beck, C.; Ünal, Ö.; Emmrich, P.; Arndt, H.J.; Greger, R. Characterization of potassium channels in respiratory cells. I. General properties. *Pflugers Arch.* **1989**, *414*, 291–296. [CrossRef]
63. Pablo, J.L.; DeCaen, P.G.; Clapham, D.E. Progress in ciliary ion channel physiology. *J. Gen. Physiol.* **2017**, *149*, 37–47. [CrossRef]
64. Kawai, F. Ca^{2+} -activated K^{+} currents regulate odor adaptation by modulating spike encoding of olfactory receptor cells. *Biophys. J.* **2002**, *82*, 2005–2015. [CrossRef] [PubMed]
65. Kume, H.; Hall, I.P.; Washabau, R.J.; Takagi, K.; Kotlikoff, M.I. Beta-Adrenergic Agonists Regulate K_{Ca} Channels in Airway Smooth Muscle by cAMP-Dependent and -Independent Mechanisms. 1994. Available online: <https://www.jci.org/articles/view/116969/scanned-page/371> (accessed on 17 March 2023).
66. Fujita, A.; Takeuchi, T.; Hanai, J.; Hata, F. Expression of the small conductance Ca^{2+} -activated K^{+} channel, SK3, in the olfactory ensheathing glial cells of rat brain. *Cell Tissue Res.* **2003**, *313*, 187–193. [CrossRef] [PubMed]
67. Collawn, J.F.; Matalon, S. CFTR and lung homeostasis. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2014**, *307*, L917–L923. [CrossRef]
68. Naeije, R.; Barberà, J.A. Pulmonary hypertension associated with COPD. *Crit. Care* **2001**, *5*, 286–289. [CrossRef] [PubMed]
69. López-Barneo, J.; del Toro, R.; Levitsky, K.L.; Chiara, M.D.; Ortega-Sáenz, P. Regulation of oxygen sensing by ion channels. *J. Appl. Physiol.* **2004**, *96*, 1187–1195. [CrossRef]
70. Franco-Obregón, A.; López-Barneo, J. Low PO_2 inhibits calcium channel activity in arterial smooth muscle cells. *Am. J. Physiol.* **1996**, *271*, H2290–H2299. [CrossRef]
71. Franco-Obregón, A.; Ureña, J.; López-Barneo, J. Oxygen-sensitive calcium channels in vascular smooth muscle and their possible role in hypoxic arterial relaxation. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 4715. [CrossRef]
72. Kume, H.; Nishiyama, O.; Isoya, T.; Higashimoto, Y.; Tohda, Y.; Noda, Y. Involvement of Allosteric Effect and K_{Ca} Channels in Crosstalk between β_2 -Adrenergic and Muscarinic M2 Receptors in Airway Smooth Muscle. *Int. J. Mol. Sci.* **2018**, *19*, 1999. [CrossRef] [PubMed]
73. Morales, B.; Labarca, P.; Bacigalupo, J. A ciliary K^{+} conductance sensitive to charibdotoxin underlies inhibitory responses in toad olfactory receptor neurons. *FEBS Lett.* **1995**, *359*, 41–44. [CrossRef]
74. Morales, B.; Madrid, R.; Bacigalupo, J. Calcium mediates the activation of the inhibitory current induced by odorants in toad olfactory receptor neurons. *FEBS Lett.* **1997**, *402*, 259–264. [CrossRef]
75. Sanhueza, M.; Schmachtenberg, O.; Bacigalupo, J. Excitation, inhibition, and suppression by odors in isolated toad and rat olfactory receptor neurons. *Am. J. Physiol. Cell Physiol.* **2000**, *279*, C31–C39. [CrossRef] [PubMed]
76. Logsdon, N.J.; Kang, J.; Togo, J.A.; Christian, E.P.; Aiyar, J. A novel gene, *hK_{Ca}4*, encodes the calcium-activated potassium channel in human T lymphocytes. *J. Biol. Chem.* **1997**, *272*, 32723–32726. [CrossRef]
77. Feske, S.; Wulff, H.; Skolnik, E.Y. Ion channels in innate and adaptive immunity. *Annu. Rev. Immunol.* **2015**, *33*, 291–353. [CrossRef] [PubMed]
78. Kaushal, V.; Koeberle, P.D.; Wang, Y.; Schlichter, L.C. The Ca^{2+} -activated K^{+} channel *KCNN4/K_{Ca}3.1* contributes to microglia activation and nitric oxide-dependent neurodegeneration. *J. Neurosci.* **2007**, *27*, 234–244. [CrossRef] [PubMed]
79. Ghanshani, S.; Wulff, H.; Miller, M.J.; Rohm, H.; Neben, A.; Gutman, G.A.; Cahalan, M.D.; Chandy, K.G. Up-regulation of the *IKCa1* Potassium Channel during T-cell Activation: Molecular Mechanism and Functional Consequences. *J. Biol. Chem.* **2000**, *275*, 37137–37149. [CrossRef] [PubMed]
80. Shao, Z.; Makinde, T.O.; Agrawal, D.K. Calcium-Activated Potassium Channel *K_{Ca}3.1* in Lung Dendritic Cell Migration. *Am. J. Respir. Cell Mol. Biol.* **2011**, *45*, 962–968. [CrossRef] [PubMed]
81. Tharp, D.L.; Wamhoff, B.R.; Turk, J.R.; Bowles, D.K. Upregulation of intermediate-conductance Ca^{2+} -activated K^{+} channel (*IKCa1*) mediates phenotypic modulation of coronary smooth muscle. *Am. J. Physiol. Heart Circ. Physiol.* **2006**, *291*, H2493–H2503. [CrossRef] [PubMed]
82. Jaggar, J.H.; Wellman, G.C.; Heppner, T.J.; Porter, V.A.; Perez, G.J.; Gollasch, M.; Kleppisch, T.; Rubart, M.; Stevenson, A.S.; Lederer, W.J.; et al. Ca^{2+} channels, ryanodine receptors and Ca^{2+} -activated K^{+} channels: A functional unit for regulating arterial tone. *Acta Physiol. Scand.* **1998**, *164*, 577–587. [CrossRef]
83. Neylon, C.B.; Lang, R.J.; Fu, Y.; Bobik, A.; Reinhart, P.H. Molecular cloning and characterization of the intermediate-conductance Ca^{2+} -activated K^{+} channel in vascular smooth muscle: Relationship between K_{Ca} channel diversity and smooth muscle cell function. *Circ. Res.* **1999**, *85*, e33–e43. [CrossRef]
84. Peña, T.L.; Rane, S.G. The fibroblast intermediate conductance K_{Ca} channel, *FIK*, as a prototype for the cell growth regulatory function of the *IK* channel family. *J. Membr. Biol.* **1999**, *172*, 249–257. [CrossRef]

85. Gerlach, A.C.; Gangopadhyay, N.N.; Devor, D.C. Kinase-dependent regulation of the intermediate conductance, calcium-dependent potassium channel, hIK1. *J. Biol. Chem.* **2000**, *275*, 585–598. [CrossRef]
86. Wulff, H.; Castle, N.A. Therapeutic potential of $K_{Ca}3.1$ blockers: An overview of recent advances, and promising trends. *Expert Rev. Clin. Pharmacol.* **2010**, *3*, 385–396. [CrossRef]
87. Srivastava, S.; Zhdanova, O.; Di, L.; Li, Z.; Albaum, M.; Wulff, H.; Skolnik, E.Y. Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K^+ channel $K_{Ca}3.1$. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 14442–14446. [CrossRef] [PubMed]
88. Cruse, G.; Duffy, S.M.; Brightling, C.E.; Bradding, P. Functional $K_{Ca}3.1$ K^+ channels are required for human lung mast cell migration. *Thorax* **2006**, *61*, 880–885. [CrossRef]
89. Roach, K.M.; Duffy, S.M.; Coward, W.; Feghali-Bostwick, C.; Wulff, H.; Bradding, P. The K^+ channel $K_{Ca}3.1$ as a novel target for idiopathic pulmonary fibrosis. *PLoS ONE* **2013**, *8*, e85244. [CrossRef] [PubMed]
90. Tarran, R. Regulation of airway surface liquid volume and mucus transport by active ion transport. *Proc. Am. Thorac. Soc.* **2004**, *1*, 42–46. [CrossRef]
91. Parasuraman, S.; Walker, S.; Loudon, B.L.; Gollop, N.D.; Wilson, A.M.; Lowery, C.; Frenneaux, M.P. Assessment of pulmonary artery pressure by echocardiography—A comprehensive review. *Int. J. Cardiol. Heart Vasc.* **2016**, *12*, 45–51. [CrossRef]
92. Wulff, H.; Kolski-Andreaco, A.; Sankaranarayanan, A.; Sabatier, J.-M.; Shakkottai, V. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. *Curr. Med. Chem.* **2007**, *14*, 1437–1457. [CrossRef] [PubMed]
93. Sørensen, U.S.; Strøbaek, D.; Christophersen, P.; Hougaard, C.; Jensen, M.L.; Nielsen, E.Ø.; Peters, D.; Teuber, L. Synthesis and structure-activity relationship studies of 2-(N-substituted)-aminobenzimidazoles as potent negative gating modulators of small conductance Ca^{2+} -activated K^+ channels. *J. Med. Chem.* **2008**, *51*, 7625–7634. [CrossRef] [PubMed]
94. Stocker, J.W.; De Franceschi, L.; McNaughton-Smith, G.A.; Corrocher, R.; Beuzard, Y.; Brugnara, C. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. *Blood* **2003**, *101*, 2412–2418. [CrossRef]
95. Agarwal, J.J.; Zhu, Y.; Zhang, Q.-Y.; Mongin, A.A.; Hough, L.B. TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. *PLoS ONE* **2013**, *8*, e63028. [CrossRef] [PubMed]
96. Simó-Vicens, R.; Kirchhoff, J.E.; Dolce, B.; Abildgaard, L.; Speerschneider, T.; Sørensen, U.S.; Grunnet, M.; Diness, J.G.; Bentzen, B.H. A new negative allosteric modulator, AP14145, for the study of small conductance calcium-activated potassium ($K_{Ca}2$) channels. *Br. J. Pharmacol.* **2017**, *174*, 4396–4408. [CrossRef]
97. Strøbaek, D.; Teuber, L.; Jørgensen, T.D.; Ahring, P.K.; Kjaer, K.; Hansen, R.S.; Olesen, S.P.; Christophersen, P.; Skaaning-Jensen, B. Activation of human IK and SK Ca^{2+} -activated K^+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime). *Biochim. Biophys. Acta* **2004**, *1665*, 1–5. [CrossRef]
98. John, C.M.; Khaddaj Mallat, R.; Mishra, R.C.; George, G.; Singh, V.; Turnbull, J.D.; Umeshappa, C.S.; Kendrick, D.J.; Kim, T.; Fauzi, F.M.; et al. SKA-31, an activator of Ca^{2+} -activated K^+ channels, improves cardiovascular function in aging. *Pharmacol. Res.* **2020**, *151*, 104539. [CrossRef] [PubMed]
99. The IKCa and SKCa Channel Activator 1-EBIO (100 μ M) Increased Outwards . . . Available online: https://www.researchgate.net/figure/The-IKCa-and-SKCa-channel-activator-1-EBIO-100-M-increased-outwards-currents-in_fig5_235718670 (accessed on 3 April 2023).
100. Dimitriadi, M.; Kye, M.J.; Kallou, G.; Yersak, J.M.; Sahin, M.; Hart, A.C. The Neuroprotective Drug Riluzole Acts via Small Conductance Ca^{2+} -Activated K^+ Channels to Ameliorate Defects in Spinal Muscular Atrophy Models. *J. Neurosci.* **2013**, *33*, 6557–6562. [CrossRef] [PubMed]
101. Kasumu, A.W.; Hougaard, C.; Rode, F.; Jacobsen, T.A.; Sabatier, J.M.; Eriksen, B.L.; Strøbaek, D.; Liang, X.; Egorova, P.; Vorontsova, D.; et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. *Chem. Biol.* **2012**, *19*, 1340–1353. [CrossRef] [PubMed]
102. Hougaard, C.; Hammami, S.; Eriksen, B.L.; Sørensen, U.S.; Jensen, M.L.; Strøbaek, D.; Christophersen, P. Evidence for a common pharmacological interaction site on $K_{Ca}2$ channels providing both selective activation and selective inhibition of the human $K_{Ca}2.1$ subtype. *Mol. Pharmacol.* **2012**, *81*, 210–219. [CrossRef]
103. Oliván-Viguera, A.; Valero, M.S.; Coleman, N.; Brown, B.M.; Laría, C.; Murillo, M.D.; Gálvez, J.A.; Díaz-de-Villegas, M.D.; Wulff, H.; Badorrey, R.; et al. A Novel Pan-Negative-Gating Modulator of $K_{Ca}2/3$ Channels, Fluoro-Di-Benzoate, RA-2, Inhibits Endothelium-Derived Hyperpolarization-Type Relaxation in Coronary Artery and Produces Bradycardia In Vivo. *Mol. Pharmacol.* **2015**, *87*, 338–348. [CrossRef] [PubMed]
104. Strøbaek, D.; Hougaard, C.; Johansen, T.H.; Sørensen, U.S.; Nielsen, E.Ø.; Nielsen, K.S.; Taylor, R.D.T.; Pedarzani, P.; Christophersen, P. Inhibitory Gating Modulation of Small Conductance Ca^{2+} -Activated K^+ Channels by the Synthetic Compound (R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) Reduces Afterhyperpolarizing Current in Hippocampal CA1 Neurons. *Mol. Pharmacol.* **2006**, *70*, 1771–1782. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.